Literature DB >> 20232364

Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma.

Sen-Yung Hsieh1, Shiu-Feng Huang, Ming-Chin Yu, Ta-Sen Yeh, Tse-Chin Chen, Yu-Jr Lin, Chee-Jen Chang, Chang-Mung Sung, Yun-Lin Lee, Chih-Yun Hsu.   

Abstract

Frequent intrahepatic metastasis causes early tumor recurrence and dismaying prognosis of human hepatocellular carcinoma (HCC). We recently identified overexpression of stathmin1 (STMN1) in human HCC. This study was designed to elucidate the clinical and biological significance of overexpression of STMN1 in HCC. Expression of STMN1 was conducted by quantitative reverse transcription-polymerase chain reaction and immunoblotting assays on 58 pairs of HCC and para-tumor liver tissues from patients with HCC along with normal liver tissues as the controls. Association of STMN1 overexpression with tumor recurrence and prognosis was investigated by Kaplan-Meier cumulative survival and Cox Regression analyses. Roles of STMN1 in cell cycle, cell motility, and invasion were determined by in vitro assays. STMN1 overexpression in hepatoma was strongly associated with local invasion (P = 0.031), early recurrence (P = 0.002), and poor prognosis (P = 0.005), and was an independent indicator for tumor recurrence (P = 0.0045). STMN1 overexpression further identified subgroups of HCC patients with higher tumor recurrence and worse prognosis among HCC patients with early tumor stage (T1) or intermediate histological grades (G2 and G3), both of whom represent the majority of HCC patients receiving primary curative hepatectomy. Silencing STMN1 expression via RNA interference suppressed invasion activity, while ectopic expression of STMN1 enhanced cell invasion and caused polyploidy of cells. In conclusion, STMN1 overexpression could predict early tumor recurrence and poor prognosis, particularly at early stage of hepatoma. Overexpression of STMN1 promoted polyploidy formation, tumor-cell invasion, and intrahepatic metastasis, suggesting that STMN1 can be a target for anti-cancer therapy of human hepatoma. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232364     DOI: 10.1002/mc.20627

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  45 in total

1.  Candidate genes involving in tumorigenesis of cholangiocarcinoma induced by Opisthorchis viverrini infection.

Authors:  Zhiliang Wu; Thidarut Boonmars; Sirintip Boonjaraspinyo; Isao Nagano; Somchai Pinlaor; Anucha Puapairoj; Puangrat Yongvanit; Yuzo Takahashi
Journal:  Parasitol Res       Date:  2011-03-05       Impact factor: 2.289

2.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

3.  A Fluorescent Live Imaging Screening Assay Based on Translocation Criteria Identifies Novel Cytoplasmic Proteins Implicated in G Protein-coupled Receptor Signaling Pathways.

Authors:  Sandra Lecat; Hans W D Matthes; Rainer Pepperkok; Jeremy C Simpson; Jean-Luc Galzi
Journal:  Mol Cell Proteomics       Date:  2015-03-10       Impact factor: 5.911

Review 4.  Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.

Authors:  Elham Hatami; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-05-31       Impact factor: 10.680

5.  Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.

Authors:  C M Fife; S M Sagnella; W S Teo; S T Po'uha; F L Byrne; Y Y C Yeap; D C H Ng; T P Davis; J A McCarroll; M Kavallaris
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

6.  High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Authors:  Henry D Reyes; Jeffrey Miecznikowski; Jesus Gonzalez-Bosquet; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Jean-Marie Stephan; Parviz Hanjani; Saketh Guntupalli; Krishnansu S Tewari; Floor Backes; Nilsa Ramirez; Gini F Fleming; Virginia Filiaci; Michael J Birrer; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2017-05-19       Impact factor: 5.482

7.  Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma.

Authors:  Han-Ping Hsu; Chien-Feng Li; Sung-Wei Lee; Wen-Ren Wu; Tzu-Ju Chen; Kwang-Yu Chang; Shih-Shin Liang; Chia-Jung Tsai; Yow-Ling Shiue
Journal:  Tumour Biol       Date:  2013-11-12

8.  Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral-mediated Tumor Growth.

Authors:  Nu T Lu; Natalie M Liu; James Q Vu; Darshil Patel; Whitaker Cohn; Joe Capri; Mary Ziegler; Nikita Patel; Angela Tramontano; Roger Williams; Julian Whitelegge; Samuel W French
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

Review 9.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

10.  Inhibition of stathmin1 accelerates the metastatic process.

Authors:  Karin Williams; Ritwik Ghosh; Premkumar Vummidi Giridhar; Guangyu Gu; Thomas Case; Scott M Belcher; Susan Kasper
Journal:  Cancer Res       Date:  2012-08-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.